{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:20Z","timestamp":1781647220469,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) accounts for most primary liver cancers and displays substantial variability in survival outcomes. Existing staging systems, such as the American Joint Committee on Cancer (AJCC), Barcelona Clinic Liver Cancer (BCLC), and China Liver Cancer Staging (CNLC) systems, often fail to capture individual heterogeneity. Additionally, many published prognostic models rely on small cohorts, predict survival at only a single timepoint, or lack temporal or external validation. Using data from the Surveillance, Epidemiology, and End Results (SEER) Program, we developed and temporally validated multi-timepoint Cox models to predict 1-, 2-, and 3-year overall survival in HCC. A total of 3850 patients diagnosed between 2018 and 2022 were included for model development and internal testing, and 2268 patients diagnosed in 2016\u20132017 formed an independent temporal validation cohort. Age, alpha-fetoprotein (AFP) level, fibrosis status, AJCC stage, and surgical treatment were identified as independent prognostic factors and incorporated into a multi-timepoint nomogram. The model achieved C-indices of 0.762, 0.760, and 0.726 in the training, test, and temporal validation cohorts. Time-dependent AUCs at 1, 2, and 3 years were 0.814, 0.801, and 0.780 in the training cohort; 0.824, 0.809, and 0.807 in the test cohort; and 0.794, 0.793, and 0.779 in the temporal validation cohort, demonstrating consistently strong discrimination. Calibration and decision curve analyses confirmed accurate agreement and clinical benefit. These findings indicate that the proposed model provides a robust tool for individualized survival prediction and risk-stratified clinical decision-making in HCC.<\/jats:p>","DOI":"10.1038\/s41598-026-48480-9","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:57:07Z","timestamp":1775894227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and temporal validation of 1-, 2-, and 3-year survival prediction models for hepatocellular carcinoma using the SEER database"],"prefix":"10.1038","volume":"16","author":[{"given":"Zixuan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keru","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"48480_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"key":"48480_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global, regional and national burden of primary liver cancer by subtype. Eur. J. Cancer. 161, 108\u2013118 (2022).","journal-title":"Eur. J. Cancer"},{"key":"48480_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"48480_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82, 315\u2013374 (2025).","journal-title":"J. Hepatol."},{"key":"48480_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","volume":"25","author":"YS Chun","year":"2018","unstructured":"Chun, Y. S., Pawlik, T. M. & Vauthey, J. N. 8th Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann. Surg. Oncol. 25, 845\u2013847 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"48480_CR6","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update. Journal Hepatology 0, (2025)."},{"key":"48480_CR7","doi-asserted-by":"publisher","DOI":"10.1159\/000546574","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 Edition). Liver Cancer. https:\/\/doi.org\/10.1159\/000546574 (2025).","journal-title":"Liver Cancer"},{"key":"48480_CR8","doi-asserted-by":"publisher","first-page":"108337","DOI":"10.1016\/j.compbiomed.2024.108337","volume":"173","author":"Z Bo","year":"2024","unstructured":"Bo, Z. et al. Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma. Comput. Biol. Med. 173, 108337 (2024).","journal-title":"Comput. Biol. Med."},{"key":"48480_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3348\/kjr.2024.0070","volume":"25","author":"S Heo","year":"2024","unstructured":"Heo, S., Park, H. J. & Lee, S. S. Prognostication of hepatocellular carcinoma using artificial intelligence. Korean J. Radiol. 25, 550\u2013558 (2024).","journal-title":"Korean J. Radiol."},{"key":"48480_CR10","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. BMJ 350, g7594\u2013g7594 (2015).","journal-title":"BMJ"},{"key":"48480_CR11","doi-asserted-by":"publisher","first-page":"1452188","DOI":"10.3389\/fmed.2024.1452188","volume":"11","author":"J Shen","year":"2024","unstructured":"Shen, J. et al. Development of prognostic models for advanced multiple hepatocellular carcinoma based on Cox regression, deep learning and machine learning algorithms. Front. Med. (Lausanne). 11, 1452188 (2024).","journal-title":"Front. Med. (Lausanne)"},{"key":"48480_CR12","doi-asserted-by":"publisher","first-page":"79442","DOI":"10.18632\/oncotarget.12722","volume":"7","author":"C Wu","year":"2016","unstructured":"Wu, C. et al. Effect of marital status on the survival of patients with hepatocellular carcinoma treated with surgical resection: An analysis of 13,408 patients in the surveillance, epidemiology, and end results (SEER) database. Oncotarget 7, 79442\u201379452 (2016).","journal-title":"Oncotarget"},{"key":"48480_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0587.2012.07348.x","volume":"36","author":"CF Dormann","year":"2013","unstructured":"Dormann, C. F. et al. Collinearity: a review of methods to deal with it and a simulation study evaluating their performance. Ecography 36, 27\u201346 (2013).","journal-title":"Ecography"},{"key":"48480_CR14","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"48480_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejso.2021.09.012","volume":"48","author":"BR Beumer","year":"2022","unstructured":"Beumer, B. R. et al. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur. J. Surg. Oncol. 48, 492\u2013499 (2022).","journal-title":"Eur. J. Surg. Oncol."},{"key":"48480_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1186\/s12885-022-09841-5","volume":"22","author":"L Li","year":"2022","unstructured":"Li, L. et al. Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: A systematic review and critical appraisal. BMC Cancer. 22, 750 (2022).","journal-title":"BMC Cancer"},{"key":"48480_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13244-024-01784-8","volume":"15","author":"Y Xia","year":"2024","unstructured":"Xia, Y. et al. CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy. Insights Imaging. 15, 214 (2024).","journal-title":"Insights Imaging"},{"key":"48480_CR18","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.59717\/j.xinn-med.2025.100125","volume":"3","author":"L Shen","year":"2025","unstructured":"Shen, L. et al. Dynamic prognostication and treatment planning for hepatocellular carcinoma: A machine learning-enhanced survival study using multi-centric data. TIME 3, 100125 (2025).","journal-title":"TIME"},{"key":"48480_CR19","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.jhepr.2022.100557","volume":"4","author":"H Toyoda","year":"2022","unstructured":"Toyoda, H. & Johnson, P. J. The ALBI score: From liver function in patients with HCC to a general measure of liver function. JHEP Rep. 4, 100557 (2022).","journal-title":"JHEP Rep."},{"key":"48480_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/JHC.S490439","volume":"12","author":"X Huang","year":"2025","unstructured":"Huang, X. et al. Prognostic value of changes in combined Child\u2013Pugh class and ALBI grade in hepatocellular carcinoma treated with transcatheter intra-arterial therapy plus targeted therapy and PD-(L)1 inhibitors. J. Hepatocell Carcinoma. 12, 481\u2013496 (2025).","journal-title":"J. Hepatocell Carcinoma"},{"key":"48480_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s10238-025-01877-8","volume":"25","author":"K N\u00fa\u00f1ez","year":"2025","unstructured":"N\u00fa\u00f1ez, K. et al. Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma. Clin. Exp. Med. 25, 328 (2025).","journal-title":"Clin. Exp. Med."},{"key":"48480_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-12075-1","author":"X Jia","year":"2025","unstructured":"Jia, X. et al. Imaging for molecular and pathological subtyping of hepatocellular carcinoma\u2014a critical appraisal and future directions. Eur. Radiol. https:\/\/doi.org\/10.1007\/s00330-025-12075-1 (2025).","journal-title":"Eur. Radiol."},{"key":"48480_CR23","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.3390\/cancers17162656","volume":"17","author":"CAM Verhagen","year":"2025","unstructured":"Verhagen, C. A. M. et al. Clinical and imaging-based prognostic models for recurrence and local tumor progression following thermal ablation of hepatocellular carcinoma: A systematic review. Cancers (Basel). 17, 2656 (2025).","journal-title":"Cancers (Basel)"},{"key":"48480_CR24","first-page":"1","volume":"149","author":"S Chidambaranathan-Reghupaty","year":"2021","unstructured":"Chidambaranathan-Reghupaty, S., Fisher, P. B. & Sarkar, D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv. Cancer Res. 149, 1\u201361 (2021).","journal-title":"Adv. Cancer Res."},{"key":"48480_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1158\/1055-9965.EPI-23-1236","volume":"33","author":"NS Wagle","year":"2024","unstructured":"Wagle, N. S. et al. Racial and ethnic disparities in hepatocellular carcinoma treatment receipt in the United States: A systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 33, 463\u2013470 (2024).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"48480_CR26","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.21037\/atm-21-6359","volume":"9","author":"X Hu","year":"2021","unstructured":"Hu, X. et al. Development and external validation of a prognostic nomogram for patients with gastric cancer after radical gastrectomy. Ann. Transl Med. 9, 1742 (2021).","journal-title":"Ann. Transl Med."},{"key":"48480_CR27","doi-asserted-by":"crossref","unstructured":"Wu, S. et al. Hepatocellular carcinoma prediction models in chronic hepatitis B: A systematic review of 14 models and external validation. Clin. Gastroenterol. Hepatol. 19, 2499\u20132513 (2021).","DOI":"10.1016\/j.cgh.2021.02.040"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48480-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48480-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48480-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:49:49Z","timestamp":1781646589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48480-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48480"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48480-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was based on publicly available, de-identified SEER data and was therefore exempt from informed consent. The study protocol was reviewed by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University and was determined to be exempt from ethical review. An official exemption certificate was issued by the committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"16443"}}